Pfizer’s XELJANZ gets FDA approval for pcJIA treatment
XELJANZ is claimed to be the only approved Janus kinase (JAK) inhibitor in the US to treat polyarticular…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
29 Sep 20
XELJANZ is claimed to be the only approved Janus kinase (JAK) inhibitor in the US to treat polyarticular…
28 Sep 20
The EC has granted marketing authorisation for Jyseleca based on data from the Phase 3 FINCH and Phase…
23 Sep 20
Ide-cel is an investigational anti-BCMA CAR T cell immunotherapy, developed under partnership between Bristol Myers Squibb and bluebird…
21 Sep 20
The positive CHMP opinion is based on results from the Phase 3 CheckMate -9LA trial, which met the…
16 Sep 20
The FDA designation enables development of Jardiance to prevent hospitalisation for heart failure and minimise the risk of…
15 Sep 20
Dupixent is a human monoclonal antibody developed by Sanofi and Regeneron to inhibit the signalling of interleukin-4 (IL-4)…
11 Sep 20
Janssen filed a supplemental Biologics License Application (sBLA) with the FDA for the approval of subcutaneous formulation of…
10 Sep 20
Trelegy Ellipta is a combination of three molecules, fluticasone furoate, umeclidinium and vilanterol (FF/UMEC/VI) for once-daily single inhalation
10 Sep 20
Of the total fine levied by the French competition watchdog totalling €444m, Novartis is expected to pay €385m…
07 Sep 20
Gavreto is a once-daily, oral precision therapy, designed to specifically act against RET alterations, fusions and mutations, irrespective…